Investing in Precision BioSciences, Inc. (DTIL)  ➔  Intrinsic value

Prev. close$12.86 
ModelValueUpside
Chepakovich$0.35-97%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$12.86  
Valuation MethodValuePotential 
Chepakovich Model$0.35-97%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company operates through two segments, Therapeutic and Food. It offers ARCUS, a genome-editing platform to cure cancers and genetic disorders. The Therapeutic segment develops allogeneic CAR T immunotherapy that recognizes and kills cancer cells; and engages in the in vivo gene correction activities. This segment develops PBCAR0191, which is in Phase 1/2a clinical trial, an allogeneic CAR T cell therapy targeting the tumor target CD19 for acute lymphoblastic leukemia and non-hodgkin lymphoma; and PBCAR20A, an allogeneic anti-CD20 CAR T for the treatment NHL, chronic lymphocytic leukemia, and small lymphocytic lymphoma, as well as developing PBCAR269A, an allogeneic anti-BCMA CAR T cell product candidate for the treatment of R/R multiple myeloma. The Food segment develops food and nutrition products. The company has a development and commercial license agreement with Shire Plc for research and development of individual T cell modifications; and a collaboration agreement with Gilead Sciences, Inc. to co-develop a product candidate to cure chronic Hepatitis B infection. Precision BioSciences, Inc. was founded in 2006 and is headquartered in Durham, North Carolina.